AACR: AbbVie's navitoclax goes after tough blood cancer, not yet reaching overall survival benchmark

Myelofibrosis is the cancer that keeps going and going—and AbbVie hopes new data from the phase 2 med navitoclax can make the case for stopping the rare and difficult-to-treat disease in its tracks.

AbbVie tested the therapy in combination with ruxolitinib in a phase 2 study called Refine that featured patients who had progressed or had a suboptimal response after at least 12 weeks of ruxolitinib alone. Ruxolitinib is a janus kinase (JAK) inhibitor marketed by Incyte as Jakafi. Refine is a dose-finding study, but efficacy outcomes are also being studied.